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We report a case of hepatocellular carcinoma (HCC) 
with pulmonary metastases treated with repeated 
hepatic arterial infusion chemotherapy (HAIC) com-
prising epirubicin and cisplatin, and systemic infusion 
of 5-fluorouracil (a modified EC/F protocol), which 
led to complete remission. A 49-year-old man with 
compensated liver cirrhosis experienced intrahepatic 
recurrence of HCC with extensive lung metastases. 
The modified EC/F therapeutic protocol, which was 
applied at the tenth cycle every 4-5 weeks, resulted 
in disappearance of the pulmonary metastases and 
normalization of serum α-fetoprotein levels. A single 
small HCC lesion was found in the left lobe of the liv-
er 13 months after the final chemotherapy session. 
HAIC with the same regimen was conducted again, 
followed by percutaneous intratumoral chemoinjection 
therapy with 5-fluorouracil and interferon-γ. Thereaf-
ter, there was no evidence of recurrence in either the 
liver or the lung, as evidenced by image analysis and 
expression of tumor markers. The disease-free inter-
vals for the liver and lung were 41 and 54 months, 
respectively. (Gut and Liver 2009;3:343-348)
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INTRODUCTION
  Hepatocellular carcinoma (HCC) is the one of the most 
common malignant cancers that occurs in worldwide. 
HCC is the third most common cause of cancer-related 
death in South Korea, where the death rate from HCC is 
22.5/100,000 of the population.
1 Although recent prog-
ress in therapeutic modalities for HCC has improved the 
prognosis of HCC to some degree,
2 the majority of pa-
tients are diagnosed with inoperable multiple intrahepatic 
and/or extrahepatic metastases, and no more than 30% of 
patients are suitable to undergo curative resection.
2
  T h e  l u n g  ( 5 5 % )  i s  t h e  m o s t  c o m m o n  s i t e  o f  e x t r a -
hepatic spread from an HCC, followed by the abdominal 
lymph nodes (41%) and bone (28%), as shown in studies 
performed in the U.S.
3 The most common site of extra-
hepatic spread from  an H CC  is the lung (67% ), follow ed 
by the bone (12%), the adrenal gland (9%) and the peri-
toneum (5%) in South Korea.
4 Although HCC has a poor 
prognosis mostly, several studies about the treatment of 
HCC with pulmonary metastases have been reported; 
however, there has been no standard therapeutic strategy 
determined for HCC with pulmonary metastases.
5-7
  In this report, we describe the case of a recurrent HCC 
with extensive lung metastases that was rapidly ag-
gravated, despite of undergoing conventional transarterial 
chemoembolization (TACE) with adriamycin. Both the in-
trahepatic HCC and pulmonary metastases were success-
fully treated with the combinated therapeutic protocol of 
monthly hepatic arterial infusion chemotherapy (HAIC) 
with epirubicin, cisplatin, and systemic infusion of 5-fluo-344   Gut and Liver, Vol. 3, No. 4, December 2009
Fig. 1. Ill-defined hypervascular tumor staining is observed in the right lobe on celiac angiography (A, B). Abdominal computed 
tomography (CT) revealed a 6.8-cm irregular-margined recurrent hepatocellular carcinoma (HCC) and a 4.4-cm low-density necrotic 
lesion that was attributable to prior radiofrequency ablation in the right lobe of liver (C, D). There was no evidence of intrahepatic
tumor recurrence on arterial- (E) and portal-phase (F) dynamic CT images after completion of chemotherapy.
rouracil (5-FU).
CASE REPORT
  A 49-year-old man was admitted to our department due 
to extensive pulmonary metastases of HCC with intra-
hepatic recurrence. The patient was initially treated with ra-
diofrequency ablation therapy 15 months prior for a single 
HCC that was 4 cm in diameter and located in segment 7 
of the liver. It was found 3 months prior that a 6.9 cm 
sized- single HCC recurred locally, with a few pulmonary 
metastases. The patient was underwent conventional TACE Oh YJ, et al: HCC with Pulmonary Metastases Treated with Repeated HAIC   345
Fig. 2. Serial chest X-rays reveal 
the reduction in the size and 
number of lung nodules be-
tween before (A), during (B), 
and after (C) chemotherapy. Se-
rial CT revealed the dramatic 
improvement in pulmonary me-
tastases between before (D), du-
ring (E), and after (F) chemo-
therapy.
with adriamycin alone twice during a one- month period. 
However, the pulmonary metastatic lesions were extensively 
aggravated. The patient had alcohol drinking history of 80 
to 150 g ethanol content by U.S. standard daily and the pa-
tient was chronically infected with hepatitis B virus. 
  On admission, general physical examinations showed 
unremarkable findings. The laboratory findings showed 
leukocyte count of 3,200/mm
3, hemoglobin level of 12.5 
g/dL and platelet count of 104,000/mm
3. The levels of as-
partate aminotransferase (AST, 36 IU/L), alanine amino-
transferase (ALT, 20 IU/L) and alkaline phosphatase 
(ALP, 188 IU/L) were normal. The total bilirubin level 
(0.5 mg/dL; normal range, 0.2-1.4 mg/dL), albumin level 
(4.4 g/dL; normal range, 3.3-5.2 g/dL), prothrombin time 
13.7 sec (80.5%; INR, 1.25) demonstrated adequate hep-
atic reserve, and then the Pugh-Child classification was 
class A. Elevation of the serum α-fetoprotein (AFP) level 
(202,530 ng/mL; normal range, 0-8.1 ng/mL) was found. 
Serum hepatitis B surface antigen (HBsAg) was positive, 
hepatitis B e antigen (HBeAg) was negative and HBV 
DNA was not detectable in serum, indicating a non-in-
fective HBV carrier status. Reaction with anti-HCV (hepa-346   Gut and Liver, Vol. 3, No. 4, December 2009
Fig. 3. Abdominal arterial-phase CT showing the new, 1-cm, enhanced HCC in the left lobe of the liver (A, B). The CT scan 
performed during the follow-up period after further chemotherapy shows complete atrophy of the hepatic tumor (C, D).
titis C virus) was negative.
    Considering both the occupation of the patient and 
HCC status, which was TNM 4b stage and CLIP score 1, 
we modified the intrahepatic arterial infusion of epi-
rubicin and cisplatin and systemic intravenous infusion of 
5-fluorouracil (EC/F) protocol for HCC that Jang et al.
8 
had reported. This protocol consisted of hepatic arterial 
infusion chemotherapy (HAIC) with the use of 50 mg/m
2 
epirubicin and 60 mg/m
2 cisplatin and systemic 12-hour 
infusion of 200 mg/m
2 5-FU. Dose modification for the 
use of epirubicin and cisplatin was calculated as follows: 
calculated dose=(dose per BSA [body surface area])× 
(leukocyte count/4000)×(1-(Pugh-Child score-5)/10)×(1 
-(age-45)/100). The patient underwent a three-day admis-
sion course each cycle. Every-4 to 5-week modified EC/ 
F-based treatment was perfomed for 10 times repeatly. 
The total accumulation doses of epirubicin and cisplatin 
were 502 mg and 600 mg, respectively. There was neither 
significant cytopenia nor decline of hepatic function with 
the use of this protocol. After the end of the second cycle 
of treatment, the serum AFP level was dramatically de-
creased from 462,704 ng/mL to 575 ng/mL. At the end 
of the sixth cycle, the serum AFP level was normalized to 
4.47 ng/dL, and also the pulmonary metastatic nodules 
had nearly disappeared (Figs. 1 and 2). The treatment 
was continued until tenth cycle as a 0.7 cm-sized isolated 
nodule was still observed in the left lower lung field in a 
dormant state. After 13 months of the disease-free inter-
val (DFI), another 1 cm-sized HCC was found in the left 
hepatic lobe. To identify another tumors that were possi-
b l y  m i s s e d  o n  C T  i m a g e s ,  w e  p e r f o r m e d  H A I C  w i t h  t h e  
same regimen and added the use of percutaneous in-
tra-tumoral chemo-injection therapy with a mixture of 
500 mg 5-FU and 4 MU interferon gamma to the target 
tumor (Fig. 3). No evidence of recurrence in both liver 
and lung was found, which was based on image analysis 
and expression of tumor markers up to December 2008. 
For liver and lung, the DFIs were 41 months and 54 Oh YJ, et al: HCC with Pulmonary Metastases Treated with Repeated HAIC   347
Fig. 4. Summary of the clinical 
course of the patient. The red 
circle indicates transarterial che-
moembolization (TACE) and the 
blue circle indicates hepatic 
arterial infusion chemotherapy 
(HAIC) with the modified epiru-
bicin, cisplatin/5-flurouracil pro-
tocol. The blue inverted triangle 
inside the quadrangle indicates 
treatment performance for HCC, 
and the inverted triangle above 
the quadrangle implies changed 
disease status (i.e., recurrence 
or metastasis). 
AFP,  α-fetoprotein; Dx, diagno-
sis; RFA, radiofrequency abla-
tion therapy; m. EC/F, modified 
EC/F protocol; PICT, percuta-
neous intra-tumoral chemo- 
injection therapy; DFI, disease- 
free interval.
months, respectively (Fig. 4).
DISCUSSION
  Although systemic chemotherapy has been used for ad-
vanced HCC, the disease has been reported to have a low 
response rate and the use of systemic chemotherapy has 
been unable to demonstrate a significant survival im-
provement.
9,10 Because most HCC patients have liver cir-
rhosis with limited hepatic reserve, the patients are not 
adequate candidates for chemotherapy and are likely to 
have more side effects associated with the cytotoxic ef-
fects of anti-cancer drugs.
11
  As almost all HCC obtain the blood supply from the 
hepatic artery, HAIC was developed as a therapeutic op-
tion for advanced HCC. Intra-arterial infusion provides a 
high concentration of drug to the tumors
12 and efficient 
d e liv e ry of d ru g s to tu m ors occu rs b y th e  u se  o f an giog-
raphy or by the use of an implanted chemoport subcuta-
neously. Administration of anti-cancer drugs is divided in-
to several sessions and can lower the dose of one-shot ar-
terial chemoinfusion, so that the systemic cytotoxicites of 
drugs can be minimized and the risk of hepatic dysfunc-
tion associated with chemotherapy can be reduced. A 
number of studies have shown a superior results for the 
use of intra-arterial chemotherapy as compared to the use 
of systemic chemotherapy.
13-15
  Drugs such as cisplatin, 5-FU, epirubicin and mitomy-
cin C have been tried as single or combination agents for 
HAIC.
8,16-18 The deoxynucleotide 5-fluoro-2'-deoxyur-
idine-5'-monophosphate derived from 5-FU blocks DNA 
synthesis by inhibiting thymidylate synthase. Cisplatin en-
hances 5-FU cytotoxicity by inhibiting intracellular L-me-
thionine metabolism and by consequently increasing the 
reduced folate pool.
19 Based on these effects, studies with 
combination chemotherapy with cisplatin and 5-FU have 
been attempted. Toyoda et al.
16 reported that the objective 
response (OR) rate of continuous local arterial infusion 
with cisplatin and 5-FU for severe advanced HCC was 
14.3%. Ando et al.
17 s h o w e d  t h a t  t h e  O R  r a t e  o f  a r t e r i a l 
i n f u s i o n  c h e m o t h e r a p y  w i t h  5 - F U  a n d  c i s p l a t i n  f o r  H C C  
with tumor thrombosis of the main trunk of the portal 
vein was 44.4%. Jang et al.
8 reported that the OR rate 
and median survival time for patients undergoing combi-
nation therapy comprised of transarterial infusion of epi-
rubicin and cisplatin, systemic infusion of 5-FU and addi-
tional percutaneous ethanol injection was higher as com-
pared to the use of conventional TACE with adriamycin 
and gelfoam in patients with unresectable HCC. In addi-
tion, Kogure et al.
18 reported a case of a patient with an 
HCC with tumor invasion to the inferior vena cava and 
multiple pulmonary metastases who was treated with the 
administration of epirubicin, cisplatin and mitomycin C 
by hepatic artery and bronchial artery infusion, which led 
to complete remission.
  I n  t h e  p r e s e n t  c a s e ,  w e  m o d if ie d  a n  o r ig in a l  p r o t o c o l  r e-
ported by Jang et al.
8 t o  r e d u c e  t h e  a d m i s s i o n  p e r i o d  b e -
cause of the occupational situation for the patient and used 348   Gut and Liver, Vol. 3, No. 4, December 2009
calculated doses of epirubicin and cisplatin for intrahepatic 
arterial infusion and one-day low fixed dose systemic in-
fusion of 5-FU. Although the HCC did not respond to adria-
mycin alone, which was used just before visiting our depart-
ment, the modified EC/F protocol showed a dramatic treat-
ment effect after the second cycle of administration. After 
the end of the sixth cycle of treatment, both liver and pul-
monary metastases had the nearly completely responds and 
the serum AFP level was normalized, as shown in Fig. 4.
  A question arises why the HCC in this case responded 
completely to the modified EC/F therapy despite both the 
non-responsiveness to adriamycin, which belongs to the 
same pharmacological group as epirubicin and the use of 
the one-day low dose 5-FU in the protocol. It may be con-
sidered that cisplatin played the main therapeutic role in 
this protocol. Several case reports have suggested that the 
use of cisplatin sometimes leads to a complete remission 
of advanced HCC with pulmonary metastases.
20-22 As the 
original EC/F therapeutic protocol demonstrated efficiency 
in the treatment of advanced HCC, it is possible that com-
bination treatment might contribute to a good result.
  In conclusion, this case indicates that chemosensitivity 
plays a more important role in HCC treatment than any 
other clinical prognostic factors, such as the AFP level, 
tumor volume, presence of metastases, vascular invasion, 
the type of administration and dosage.
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